SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Rationing tests for drug-resistant tuberculosis - who are we prepared to miss?

Martin, LJ; Roper, MH; Grandjean, L; Gilman, RH; Coronel, J; Caviedes, L; Friedland, JS; Moore, DAJ (2016) Rationing tests for drug-resistant tuberculosis - who are we prepared to miss? BMC Med, 14. p. 30. ISSN 1741-7015 https://doi.org/10.1186/s12916-016-0576-8
SGUL Authors: Friedland, Jonathan Samuel

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

BACKGROUND: Early identification of patients with drug-resistant tuberculosis (DR-TB) increases the likelihood of treatment success and interrupts transmission. Resource-constrained settings use risk profiling to ration the use of drug susceptibility testing (DST). Nevertheless, no studies have yet quantified how many patients with DR-TB this strategy will miss. METHODS: A total of 1,545 subjects, who presented to Lima health centres with possible TB symptoms, completed a clinic-epidemiological questionnaire and provided sputum samples for TB culture and DST. The proportion of drug resistance in this population was calculated and the data was analysed to demonstrate the effect of rationing tests to patients with multidrug-resistant TB (MDR-TB) risk factors on the number of tests needed and corresponding proportion of missed patients with DR-TB. RESULTS: Overall, 147/1,545 (9.5%) subjects had culture-positive TB, of which 32 (21.8%) had DR-TB (MDR, 13.6%; isoniazid mono-resistant, 7.5%; rifampicin mono-resistant, 0.7%). A total of 553 subjects (35.8%) reported one or more MDR-TB risk factors; of these, 506 (91.5%; 95% CI, 88.9-93.7%) did not have TB, 32/553 (5.8%; 95% CI, 3.4-8.1%) had drug-susceptible TB, and only 15/553 (2.7%; 95% CI, 1.5-4.4%) had DR-TB. Rationing DST to those with an MDR-TB risk factor would have missed more than half of the DR-TB population (17/32, 53.2%; 95% CI, 34.7-70.9). CONCLUSIONS: Rationing DST based on known MDR-TB risk factors misses an unacceptable proportion of patients with drug-resistance in settings with ongoing DR-TB transmission. Investment in diagnostic services to allow universal DST for people with presumptive TB should be a high priority.

Item Type: Article
Additional Information: © 2016 Martin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Drug Susceptibility Testing, Microscopic-observation drug-susceptibility assay, Multidrug-resistant tuberculosis, Tuberculosis, Adult, Diagnostic Tests, Routine, Female, Health Care Rationing, Health Resources, Health Services Accessibility, Health Status Disparities, Humans, Male, Mass Screening, Microbial Sensitivity Tests, Middle Aged, Mycobacterium tuberculosis, Risk Factors, Sputum, Treatment Outcome, Tuberculosis, Multidrug-Resistant, Sputum, Humans, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Diagnostic Tests, Routine, Mass Screening, Treatment Outcome, Microbial Sensitivity Tests, Risk Factors, Health Care Rationing, Adult, Middle Aged, Health Resources, Health Services Accessibility, Female, Male, Health Status Disparities, Microscopic-observation drug-susceptibility assay, Multidrug-resistant tuberculosis, Tuberculosis, Drug Susceptibility Testing, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, Microscopic-observation drug-susceptibility assay, Multidrug-resistant tuberculosis, Tuberculosis, Drug Susceptibility Testing, MYCOBACTERIUM-TUBERCULOSIS, COST-EFFECTIVENESS, SUSCEPTIBILITY ASSAY, DIAGNOSIS, STRATEGIES, PERU, 11 Medical And Health Sciences, General & Internal Medicine
Journal or Publication Title: BMC Med
ISSN: 1741-7015
Language: eng
Dates:
DateEvent
23 March 2016Published
3 February 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MR/K007467/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
078067Wellcome Trusthttp://dx.doi.org/10.13039/100004440
TW006581FIC NIH HHSUNSPECIFIED
D43 TW006581FIC NIH HHSUNSPECIFIED
064672Wellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 27005771
Web of Science ID: WOS:000373172500001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/110618
Publisher's version: https://doi.org/10.1186/s12916-016-0576-8

Actions (login required)

Edit Item Edit Item